Related Experiment Video
Updated: Jun 22, 2026
05:43
Real-Time Dynamic Collection of Hippocampal Extracellular Fluid from Conscious Rats Using a Microdialysis System
Published on: October 21, 2022
Emerging drugs for hepatic encephalopathy.
Oliviero Riggio1, Lorenzo Ridola
1Sapienza Università di Roma, Dipartimento di Medicina Clinica, II Gastroenterologia, Viale dell' Università 37, 00185 Roma, Italy. oliviero.riggio@uniroma1.it
Expert Opinion on Emerging Drugs
|June 26, 2009
Summary
Current treatments for hepatic encephalopathy (HE) lack strong clinical trial support. Further research is needed to develop effective therapies and prevention strategies for this severe cirrhosis complication.
Area of Science:
- Hepatology
- Gastroenterology
- Clinical Trials Methodology
Background:
- Hepatic encephalopathy (HE) is a serious complication of cirrhosis impacting patient quality of life.
- Current treatments targeting gut-derived toxins like ammonia lack definitive clinical trial evidence.
- There is a need for improved therapeutic strategies and evidence-based interventions for HE.
Purpose of the Study:
- To review existing and potential future therapeutic strategies for HE.
- To identify unmet medical needs in HE management.
- To propose optimal designs for randomized controlled trials (RCTs) in HE.
Main Methods:
- Literature review of existing RCTs and animal studies on HE.
- Analysis of HE pathophysiology to inform future therapeutic hypotheses.
- Evaluation of current approaches and their supporting evidence.
Main Results:
- Existing therapeutic approaches for HE are under debate due to limited clinical trial data.
- Information from clinical trials does not currently support specific treatments for HE.
- Further research is required to validate promising new treatment modalities.
Conclusions:
- Improved competence in conducting RCTs with clinically relevant endpoints for HE is crucial.
- Studies are needed to determine if HE can be prevented in at-risk patients.
- RCTs on intestinal flora modulators and adsorbent systems require further investigation.
More Related Videos
Related Concept Videos
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...